Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyResearch in context

• Главные авторы: Xiaoling Cai (Автор), Linong Ji (Автор), Mingxia Yuan (Автор), Jianhua Ma (Автор), Fang Bian (Автор), Sheli Li (Автор), Wuyan Pang (Автор), Shuang Yan (Автор), Huimin Zhou (Автор), Minghui Hou (Автор), Wenhui Li (Автор), Ying Jia (Автор), Li Liu (Автор), Ke Ding (Автор), Michael Xu (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2024-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Summary: Background: Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We aimed to evaluate the efficacy and safety of visepe...